tech
mRNA cancer vaccine reduces melanoma recurrence in major study
An mRNA cancer vaccine from Moderna and Merck reduces melanoma recurrence by 42 per cent in a major study.
Moderna and Merck released study results on Thursday regarding a personalized mRNA cancer vaccine. The treatment, called intismeran, reduced the risk of melanoma returning by 42 per cent two years after surgery when combined with immunotherapy. Dr. Hussein Tawbi of MD Anderson Cancer Center described the outcome as a big win for the field. The companies moved the data release forward from a planned Saturday meeting in Madrid following a leak.
Latest updates
mRNA cancer vaccine reduces melanoma recurrence in major study
A first-of-its-kind mRNA cancer vaccine has demonstrated a significant reduction in the recurrence of melanoma tumors. The results, released Thursday by Moderna and Merck, indicate the vaccine is most effective when combined with existing standard treatments. This study marks a major milestone in personalized cancer therapy. Further clinical evaluations are expected to determine the long-term efficacy of the treatment.